(Q35554389)

8 August 2017

title

Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management (English)

1 reference

8 August 2017

0 references

1 reference

1

Margaret Rosenfeld

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14534401

19 March 2024

author name string

Bonnie W. Ramsey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14534401

19 March 2024

Ronald L. Gibson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14534401

19 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14534401

19 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://journals.lww.com/00063198-200311000-00008

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Current Opinion in Pulmonary Medicine

19 March 2024

published in

1 reference

8 August 2017

volume

9

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

492-497

1 reference

Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors

19 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

19 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis

19 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

19 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis

19 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis

19 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients.

19 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis

19 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada.

19 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

19 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis

19 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.

19 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa

19 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa

19 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype

19 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Predictors of deterioration of lung function in cystic fibrosis

19 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection

19 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis--prognostic significance

19 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Early airway infection, inflammation, and lung function in cystic fibrosis.

19 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

19 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

19 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

19 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Lung function testing in infants with cystic fibrosis: lessons from the past and future directions

19 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Flow limitation in normal infants: a new method for forced expiratory maneuvers from raised lung volumes

19 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis.

19 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Spirometry in 3- to 6-year-old children with cystic fibrosis

19 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Wisconsin cystic fibrosis chest radiograph scoring system: validation and standardization for application to longitudinal studies.

19 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate

19 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

19 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

19 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

19 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

19 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization

19 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group

19 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Quinolone arthropathy in animals versus children

19 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome

19 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis

19 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

19 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Nebulization and anti-Pseudomonas aeruginosa activity of colistin

19 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis

19 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis

19 March 2024

44

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

19 March 2024

45

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

19 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

Diagnosis and treatment of cystic fibrosis

19 March 2024

47

1 reference

https://api.crossref.org/works/10.1097/00063198-200311000-00008

19 March 2024

Identifiers

1 reference

8 August 2017

1 reference